Not available outside of the UK & Ireland.
Application
Ranolazine dihydrochloride has been used:as a low Torsades-de-pointes (TdP) risk drug to study its effects on QTc prolongation, electrocardiographic (PR and QRS) intervals in dog cardiovascular modelas a partial fatty acid oxidation(FAO) inhibitor to study its effects on glioblastoma cellsas a late sodium(Na+)-current (INaL) inhibitor to study its effects on atrial tachycardia in rabbit heart
Biochem/physiol Actions
pFOX (partial fatty acid oxidation) inhibitor, a new class of anti-anginal drugs, which inhibit fatty acid beta-oxidation and activates pyruvate dehydrogenase, thereby diverting the heart′s energy source from lipids to glucose, which requires less oxygen and helps maintain myocardiac function at times of ischemia
Ranolazine is a derivative of anti-ischemic piperazine and acts as sodium (Na+)-current inhibitor. It has the potential to treat diastolic heart failure and helps in ameliorating myocardial diastolic function.
Features and Benefits
This compound was developed by Gilead. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Packaging
100, 500 mg in glass bottle
This product has met the following criteria to qualify for the following awards: